Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
2006 1
2012 1
2013 1
2014 2
2015 9
2016 3
2017 18
2018 30
2019 41
2020 48
2021 55
2022 59
2023 51
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW, Read C. Armstrong AW, et al. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. JAMA. 2020. PMID: 32427307 Review.
Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab). Biologics that i …
Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bi …
New Treatment Addressing the Pathogenesis of Psoriasis.
Tokuyama M, Mabuchi T. Tokuyama M, et al. Int J Mol Sci. 2020 Oct 11;21(20):7488. doi: 10.3390/ijms21207488. Int J Mol Sci. 2020. PMID: 33050592 Free PMC article. Review.
The effectiveness of biologic treatments such as tumor necrosis factor (TNF)alpha inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have …
The effectiveness of biologic treatments such as tumor necrosis factor (TNF)alpha inhibitors (infliximab, adalimumab, certolizumab pegol), I …
The Psoriasis Decision Tree.
Monks G, Rivera-Oyola R, Lebwohl M. Monks G, et al. J Clin Aesthet Dermatol. 2021 Apr;14(4):14-22. Epub 2021 Apr 1. J Clin Aesthet Dermatol. 2021. PMID: 34055182 Free PMC article. Review.
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Ruggiero A, et al. Clin Cosmet Investig Dermatol. 2022 Aug 16;15:1649-1658. doi: 10.2147/CCID.S364640. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 35996400 Free PMC article. Review.
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. ...Herein, we performed a comprehensive literature review about real-life data available on guse …
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. PMID: 35603936 Free PMC article. Updated. Review.
Infliximab, anti-IL17 drugs (bimekizumab, ixekizumab, secukinumab and brodalumab) and anti-IL23 drugs (risankizumab and guselkumab) except tildrakizumab showed a higher proportion of patients reaching PASI 90 than ustekinumab and three anti-TNF alpha agents (adalimumab, ce …
Infliximab, anti-IL17 drugs (bimekizumab, ixekizumab, secukinumab and brodalumab) and anti-IL23 drugs (risankizumab and guselkumab) except …
Tildrakizumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000026 Free Books & Documents. Review.
No information is available on the clinical use of tildrakizumab during breastfeeding. Because tildrakizumab is a large protein molecule with a molecular weight of 147,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroye …
No information is available on the clinical use of tildrakizumab during breastfeeding. Because tildrakizumab is a large protei …
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. Nast A, et al. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915. J Eur Acad Dermatol Venereol. 2020. PMID: 33349983
The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinum …
The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, b …
A non-clinical comparative study of IL-23 antibodies in psoriasis.
Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, Gauld S, Konrad M, Leys L, McCarthy R, Namovic M, Nelson C, Overmeyer G, Perron D, Su Z, Wang L, Westmoreland S, Zhang J, Zhu R, Veldman G. Zhou L, et al. MAbs. 2021 Jan-Dec;13(1):1964420. doi: 10.1080/19420862.2021.1964420. MAbs. 2021. PMID: 34460338 Free PMC article.
Risankizumab and guselkumab exhibited 5-fold higher affinity for IL-23 and showed more potent inhibition of IL-23 signaling than ustekinumab and tildrakizumab. Risankizumab and guselkumab completely blocked the binding of IL-23 to IL-23Ralpha as expected, whereas tildra …
Risankizumab and guselkumab exhibited 5-fold higher affinity for IL-23 and showed more potent inhibition of IL-23 signaling than ustekinumab …
Tildrakizumab.
[No authors listed] [No authors listed] 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643619 Free Books & Documents. Review.
Tildrakizumab is humanized monoclonal antibody to interleukin-23 that is used to treat moderate-to-severe plaque psoriasis. Tildrakizumab is associated with a low rate of transient and asymptomatic serum enzyme elevations during therapy, but has not been linked to c …
Tildrakizumab is humanized monoclonal antibody to interleukin-23 that is used to treat moderate-to-severe plaque psoriasis. Tildra …
Tildrakizumab (Ilumya).
[No authors listed] [No authors listed] 2023 Feb. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2023 Feb. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 35952251 Free Books & Documents. Review.
This sheet is about exposure to tildrakizumab in pregnancy and while breastfeeding. This information is based on available published literature. ...
This sheet is about exposure to tildrakizumab in pregnancy and while breastfeeding. This information is based on available published …
294 results